Track Hepion Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Hepion Pharmaceuticals, Inc. HEPA · Stock Open Hepion Pharmaceuticals, Inc. in new tab

0.1050 USD
P/E
0.06
EPS
-0.19
P/B
-8.14
ROE
-125.64
Beta
1.69
Loading chart...
Key Metrics
Earnings dateMarch 3, 2027
P/E0.06
EPS-0.19
Book Value-0.01
Price to Book-8.14
Debt/Equity2.03
% Insiders63.301%
Estimates
Forward P/E-0.01
Forward EPS-11.43

DCF valuation

Model fair value for Hepion Pharmaceuticals, Inc. (HEPA)
Result
Sign in to run the valuation for HEPA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Hepion Pharmaceuticals, Inc. Logo Hepion Pharmaceuticals, Inc. Analysis (HEPA)

United States Health Care Official Website Stock

Is Hepion Pharmaceuticals, Inc. a good investment? Hepion Pharmaceuticals, Inc. (HEPA) is currently trading at 0.1050 USD.

In terms of valuation, the stock trades at a P/E ratio of 0.06. This relatively low multiple may signal that Hepion Pharmaceuticals, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Hepion Pharmaceuticals, Inc. is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is -11.43.

Investor FAQ

Does Hepion Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Hepion Pharmaceuticals, Inc.?

Hepion Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of -0.19.

Company Profile

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. It also operates as a biotech research development company. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.

Exchange Ticker
NMS (United States) HEPA
FRA (Germany) 336P.F
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
May 29, 2018 Needs review
June 3, 2019 1:100
May 11, 2023 1:20
March 18, 2025 1:50
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion